General Information of Drug (ID: DMLGKYI)

Drug Name
PMID30185082-Compound-56 Drug Info
Cross-matching ID
PubChem CID
17756659
TTD Drug ID
DMLGKYI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MIN-101 DMCJY35 Schizophrenia 6A20 Phase 3 [2]
CT1812 DMBRKZ7 Alzheimer disease 8A20 Phase 2 [3]
Isoindoline derivative 5 DMIUTQW N. A. N. A. Patented [1]
Isoindoline derivative 3 DM2MYL9 N. A. N. A. Patented [1]
Isoindoline derivative 4 DMP1NKI N. A. N. A. Patented [1]
Isoindoline derivative 2 DMTE0S3 N. A. N. A. Patented [1]
Isoindoline derivative 1 DMD19QC N. A. N. A. Patented [1]
Benzamide derivative 9 DMVFSJZ N. A. N. A. Patented [1]
Benzamide derivative 10 DM9PKU2 N. A. N. A. Patented [1]
PMID30185082-Compound-57 DMNDF1Z N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sigma intracellular receptor 2 (TMEM97) TT9NXW4 SGMR2_HUMAN Ligand [1]

References

1 The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)